Patient Group Direction
|
|
- Jodie Lloyd
- 5 years ago
- Views:
Transcription
1 This Patient Group Direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used. Patient Group Direction for the supply and administration of COMBINED HEPATITIS A and TYPHOID VACCINE (for the purpose of travel only) Brands - HEPATYRIX Vaccine ViATIM Vaccine by a registered Nurse for Adults and Adolescents aged 15 years and above (HEPATYRIX ) Adults and Adolescents aged 16 years and above (ViATIM ) PGD Version 6 Valid from 1 May 2015 Expiry Date 30 April 2017 Supersedes Combined Hepatitis A and Typhoid Vaccine PGD Version 5.0 Change history Version number Change details 6 Format update as per NICE guidance for PGDs. Content update in accordance with GB Chapter 17 (updated Dec 2013) and Chapter 33 (updated Oct 2014) and Summary of Product Characteristics revisions. MHRA revised advice for reporting Adverse Drug Reactions Date Expiry date: 30 April
2 PGD development Developed and Produced by the Cheshire, Mersey & Greater Manchester Immunisation PGD Group: Organisation Professional group Current group member PHE Cheshire, Warrington & Wirral Screening & Immunisation Manager Lynn Simpson PHE Merseyside Immunisation Co-ordinator Michelle Falconer 5 Boroughs Partnership Governance Pharmacist Carol Humphries Liverpool Community Health Trust North West Commissioning Support Unit V&I Lead Nurse Senior Pharmacist Tracey Hart Helen Stubbs North West CSU Pharmacist Jo Bark-Jones PHE Cheshire & Merseyside PHE Cheshire & Merseyside PHE Merseyside Warrington CCG PHE Greater Manchester PHE Greater Manchester PHE Greater Manchester Deputy Director for Public Health Senior Health Protection Nurse Screening & Immunisation Manager Practice Nurse (for travel vaccines PGD review only) Screening & Immunisation Manager Screening and Immunisation Coordinator Screening and Immunisation Coordinator Dr S Ghebrehewet Gill Marsh Pauline Jones Angela Dickin Graham Munslow Catherine Hay Pam Southcombe Expiry date: 30 April
3 PGD Signatories and Authorisation PGD Authorisation Organisational Authorisation by Name: Dr Philip Jennings Position: Deputy Medical Director NHS England (Cheshire & Merseyside) Optional local Signatory Signature: Date: 05/05/2015 Name: Position: Signature: Date: Expiry date: 30 April
4 Training and competency of registered health professionals Qualifications and professional registration Requirements of registered health professionals working under the PGD Nurses currently registered with the Nursing and Midwifery Council (NMC) Initial training Received training to undertake supply and administration of medicines under Patient Group Directions. Competency assessment Ongoing training and competency Received appropriate training and updates on the administration of immunisations, in accordance with local policy and national PHE guidance, and can demonstrate competence in these areas. Received appropriate training and updates on resuscitation and management of anaphylaxis and demonstrates competence in this area. Received appropriate training and updates on the storage of vaccines, in accordance with the local cold chain policy, and can demonstrate competence in this area. The individual s competence to immunise should have been assessed in accordance with competency standards, for example, the RCN quality framework RCN 2013 (see reference), by an appropriate clinician/line manager before immunising under this PGD. Clinicians and line managers must ensure they assess the knowledge and competence of each staff member delivering vaccinations and keep a record of staff training requirements. Access annual training updates on resuscitation skills and the management of anaphylaxis in the community. Able to provide evidence of continued professional development i.e. meeting Post-Registration Education & Practice (PREP) requirements. Practitioners should be constantly alert to any subsequent recommendations from the Department of Health and Joint Committee on Vaccination and Immunisation, including tripartite letters, additional immunisation advice / campaigns, product updates and updates to the Department of Health Green Book. Practitioners are advised to register for the PHE Vaccine Update electronic newsletter via the website, which will assist signposting to the latest information. Information in such documents supersedes information within the PGD and should be followed. However if this advice affects the inclusion /exclusion criteria, then the practitioner MUST seek a PSD until the PGD has been revised. Expiry date: 30 April
5 Clinical condition Clinical condition or situation to which this PGD applies Inclusion criteria Active immunisation against invasive disease caused by Hepatitis A and Typhoid Fever. Pre-exposure: Individuals who require protection against both typhoid and Hepatitis A who are Travelling to or going to reside in areas of moderate or high endemnicity for Hepatitis A, particularly where sanitation and food hygiene may be poor AND Travelling to typhoid endemic areas where planned activities put the individual at higher risk Exclusion criteria A confirmed anaphylactic reaction to a previous dose of vaccine containing the same antigens A confirmed anaphylactic reaction to any component of the vaccine (for previous severe hypersensitivity reactions to non-vi typhoid vaccine see Cautions) No Valid Consent Pregnancy - PSD will be required following a risk assessment) HEPATYRIX - Children under age of 15 years. ViATIM - Children under the age of 16 years. Received a dose of typhoid containing vaccine in the last 3 years Received a dose of Hepatitis containing vaccine in the last 6 months Under age 15 (Hepatyrix ) Under age 16 (Viatim ) NB. Exclusion under this PGD does not necessarily mean the vaccine is contraindicated. Expiry date: 30 April
6 Cautions (including any relevant action to be taken) Cautions (including any relevant action to be taken) - continued Arrangements for referral for medical advice Current acute febrile illness immunisation should be postponed until recovered individuals with known hypersensitivity to neomycin (a residual of the manufacturing process) Breast feeding o No data are available on the safety of Vi polysaccharide typhoid vaccines in pregnancy or breast feeding. There is no evidence of risk from vaccinating pregnant women or those who are breast-feeding with inactivated viral or bacterial vaccines or toxoids. If the risk of typhoid is high, vaccination should be considered- a risk assessment should be carried out Individuals who are immunosuppressed due to disease, e.g. HIV, Hodgkins, or treatment e.g. corticosteroids therapy may not achieve an adequate immune response and may require additional doses - SEEK ADVICE This vaccine protects against Typhoid Fever caused by Salmonella Enterica serotype Typhi and does not protect against Paratyphoid Fever Administer inactivated vaccine at least 2 weeks prior to risk of exposure to Typhoid or hepatitis A. However if a patient presents for travel advice less than two weeks before travel they should still be offered vaccination. The importance of good personal, food and water hygiene must be emphasised to this group of patients as their vaccine response may not be maximal prior to departure NB severe reactions to a previous dose of non -Vi Typhoid vaccine does not contraindicate to the subsequent use of a Vi-Typhoid containing vaccine. Most severe reactions to Typhoid vaccines will have been associated with the inactivated whole cell type, which are no longer available in the UK. Refer to appropriate clinician in accordance with local arrangements e.g. GP, paediatrician Action to be taken if patient excluded Advise when patient may receive vaccine Advise regarding risks of Hepatitis A and Typhoid Fever and disease transmission, signs and symptoms Document exclusion in notes Immunise as soon as valid consent is obtained if appropriate Expiry date: 30 April
7 Seek specialist advice if necessary. Action to be taken if patient declines treatment Document refusal and action taken in patient s record Advise regarding risks of Hepatitis A and Typhoid Fever and disease transmission signs and symptoms Advise on hygiene and avoiding hepatitis A and typhoid Provide information about protective effects of vaccine. If travelling advise to take all necessary precautions to avoid contact with or ingestion of potentially contaminated water or food Expiry date: 30 April
8 Details of the medicine Name, form and strength of medicine Legal category Black triangle Indicate any off-label use (if relevant) Route/method of administration Dose and frequency Combined Hepatitis A and Typhoid Vaccine. ViATIM Hepatitis A adsorbed 160 antigen units and typhoid polysaccharide 25 micrograms vaccine. A dual chamber pre-filled syringe containing a cloudy white suspension and a clear colourless solution. Hepatyrix Hepatitis A adsorbed 1440 ELISA units and typhoid polysaccharide 25 micrograms vaccine is a slightly opaque white suspension in a pre-filled syringe. POM No Not applicable. Intramuscular injection. Individuals with a bleeding disorder may have vaccine by deep subcutaneous injection to reduce risk of bleeding (see SPC for detail) ViATIM Shake to ensure thorough mixing of the suspension. The contents of the two syringes are mixed immediately prior to administering. Hepatyrix should be shaken well before it is injected. Hepatyrix 1ml dose adults and adolescents aged 15 years and older ViATIM 1ml dose - adults and adolescents aged 16 years and older Primary vaccination Administer a single dose of vaccine at least 2 weeks prior to risk of exposure to Hepatitis A and Typhoid. If a patient presents for travel advice less than two weeks before travel they should still be offered vaccination. Reinforcing Doses Expiry date: 30 April A booster dose of an inactivated hepatitis A vaccine is recommended 6 to 12 months after a single dose of Hepatyrix or ViATIM, to provide long term protection against hepatitis A virus, (see single vaccine Hepatitis A PGD) 6 to 12 months after primary immunisation with Hepatitis A vaccine, Hepatyrix or ViATIM may be used to boost Hepatitis A in individuals who also require priming dose against Typhoid Fever. These boosters given 6 12 months after a primary dose will give immunity from Hepatitis A for up to 20 years.
9 Dose and frequency continued Either Hepatyrix or ViATIM may be used as a reinforcing dose when protection from both hepatitis A and typhoid is required Subjects who remain at risk of typhoid fever should be revaccinated using a single dose of Vi polysaccharide vaccine every 3 years (see single vaccine Typhoid PGD). Quantity to be administered and/or supplied Maximum or minimum treatment period Adverse effects Additional Facilities Storage and Disposal Delayed administration of the booster dose Ideally, the manufacturers recommended timing for the administration of the booster dose of hepatitis A vaccine should be followed. In practice, and particularly in infrequent travellers, there may be a delay in accessing this injection. Studies have shown that successful boosting can occur even when the second dose is delayed for several years so a course does not need to be re-started. Refer to dose and frequency section above. Not applicable Adverse reactions are usually mild and confined to the first few days. Most common reactions are mild transient soreness, erythema, and induration at injection site. This list is not exhaustive refer to current BNF and SPC for complete list. All suspected ADRs that are serious or result in harm should be reported via yellow card system. Serious reactions are those that are fatal, lifethreatening, disabling or incapacitating, those that cause a congenital abnormality or result in hospitalisation, and those that are considered medically significant for any other reason Immediate access to Adrenaline 1 in 1000 injection. The vaccine should be maintained at a temperature of +2ºC to +8ºC and protected from light. Freezing may cause loss of potency rendering the vaccine non effective. It can also cause hairline cracks in the container, leading to contamination of the contents. If there is a potential that the vaccine has been frozen it should be discarded as special waste. Disposal should be by incineration - as per the local waste policy. In the event of any vaccines being stored outside of the recommended +2ºC to +8ºC, this should be reported Expiry date: 30 April
10 Storage and disposal continued Records to be kept and actions taken according to the local Cold Chain policy. These vaccines cannot be given using this PGD. Record fully in Trust clinical record / GP records and as required in parent held records. Patient name and date of birth. Dose, site and route of administration. Antigen(s) given, brand, batch and expiry date of vaccine. Date and time given and by whom. Consent obtained. Stage of immunisation (if appropriate) and if/when next dose is due. An indication that the vaccine has been administered under a PGD. Advice given. Immuniser s signature on appropriate record/ password controlled immunisers record on patient e-records. An electronic or manual record of all individuals receiving immunisation under this PGD should be kept for audit purposes. Patient information Written and verbal information to be given to patient or carer Follow-up advice to be given to patient or carer Inform of possible side effects and their management. Supply Patient Information Leaflet. Emphasise good personal, food and water hygiene; Advise to take all necessary precautions to avoid contact with or ingestion of potentially contaminated water or food. Use the opportunity to provide advice on other preventative measures or to arrange referral to appropriate specialist services. Inform of timings of subsequent vaccines if appropriate. Expiry date: 30 April
11 Appendices Appendix A - Key References 1. NMC (2010) Standards for Medicines Management 2. NMC (2015) The Code of Professional Conduct 3. RCN (2013) Supporting the delivery of immunisation education. A quality framework to support the implementation of national standards and guidelines on immunisation training 4. ebnf at Summary of Product Characteristics a. Hepatyrix 16 March 2015 (accessed 17 April 2015) b. ViATIM 2 March 2015 (accessed 17 April 2015) 6. Immunisation Against Infectious Disease The Green Book including updated Chapter 17 (accessed ) and Chapter 33 (accessed ) 7. RCN 2013 Supporting the delivery of immunisation education. A quality framework to support the implementation of national standards and guidelines on immunisation training 8. NICE Competency Framework for Health Professionals using PGDs (Jan 2014). Expiry date: 30 April
12 Appendix B - Health Professionals Agreement to Practise Both the Health Professional and the Senior Representative must be familiar with the NICE competency framework for Health Professionals using PGDs (Jan 2014) before signing this agreement. Health Professional Name I have read and understood the Patient Group Direction and agree to supply and/or administer this medicine only in accordance with this PGD Signature Date Senior Representative (Clinical) Name I give authorisation on behalf of the NHS organisation / Group Practice for the named Health Professional who has signed this PGD to administer the vaccine as prescribed within this direction and in accordance with the local governance policy for PGDs, and current Public Health guidance (The Green Book - Immunisation against Infectious Disease) available at Signature Date Expiry date: 30 April
Patient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of COMBINED HEPATITIS A AND HEPATITIS B VACCINE TWINRIX PAEDIATRIC For Children aged 1 year to under 16 years TWINRIX ADULT For Adults and Adolescents
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Vi Capsular Polysaccharide Typhoid Vaccine(Ty2) Brands TYPHERIX Vaccine TYPHIM Vi Vaccine To adults and/or children over 2 years of age Or Oral
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of HAEMOPHILUS INFLUENZAE TYPE B AND MENINGOCOCCAL C CONJUGATE VACCINE (HIB-MenC) MENITORIX Vaccine By Registered Nurse/Midwife/Health Visitor
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Adsorbed low dose DIPHTHERIA/TETANUS/acellular PERTUSSIS/ inactivated POLIO REPEVAX Vaccine (dtap/ipv) Or Adsorbed DIPHTHERIA/TETANUS/acellular
More informationPatient Group Direction
Patient Group Direction For the supply and administration of PNEUMOCOCCAL POLYSACCHARIDE VACCINE (23 VALENT) PNEUMOVAX II Vaccine By Registered Nurse/Midwife/Health Visitor To Adults and children over
More informationPatient Group Direction For the supply and administration of
Patient Group Direction For the supply and administration of Adsorbed low dose DIPHTHERIA/TETANUS/acellular PERTUSSIS/ inactivated POLIO REPEVAX Vaccine (dtap/ipv) By Registered Nurse/Midwife/Health Visitor
More informationPatient Group Direction for HEPATITIS A AND TYPHOID VACCINE. Version No.: 4/2014. Hitesh Patel Pharmaceutical Adviser, NHS Telford & Wrekin CCG
Document Title: Patient Group Direction for HEPATITIS A AND TYPHOID VACCINE PCT Doc Ref.: Local Doc Ref.: PGD Version No.: 4/2014 Author/Owner: File Reference: Document Overseeing Group: Hitesh Patel Pharmaceutical
More informationDocument Details Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No Local Ref (optional) Main points the
Document Details Title Patient Group Direction Hepatitis A vaccine (Havrix Monodose ) Trust Ref No 1506-41174 Local Ref (optional) Main points the Active immunisation against infection caused by Hepatitis
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Hepatitis B Vaccine (Engerix ) Trust Ref No 1505-41182 Local Ref (optional) Main points the Immunisation against Hepatitis B document covers Who is
More informationThis document expires on Patient Group Direction No. VI 7
Patient Group Direction (PGD) for The Administration of Combined low-dose Diphtheria, Tetanus, and Inactivated Polio Vaccine (Revaxis ) to individuals aged over 10 years, by Registered Nurses employed
More informationPATIENT GROUP DIRECTION. Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif )
PATIENT GROUP DIRECTION Administration of: Oral (live attenuated) Typhoid Vaccine (Ty21a) (Vivotif ) By: Practice Nurses In: General Practice It is the responsibility of the professional working under
More informationGG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1338 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationPatient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B Start Date: 1 st January 2014 Expiry Date: 31 st December 2015
Patient Group Direction for Combined Hepatitis A & B vaccine Version: Hep A + B 2014.1 Start 1 st January 2014 Expiry 31 st December 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationPatient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start Date: 1 st July 2015 Expiry Date:30 th June 2018
Patient Group Direction Hepatitis A vaccine Version: Hepatitis A 2015 Start 1 st July 2015 Expiry 30 th June 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: BLACKPOOL
More informationThis document expires on Patient Group Direction No. VI 5
Patient Group Direction (PGD) for The Administration of Combined Adsorbed Diphtheria, Tetanus, Pertussis, (Acellular Component) and Inactivated Poliomyelitis Vaccine (Infanrix-IPV ) to children aged between
More informationSAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein
Patient Group Direction for the supply or administration of haemophilus influenzae type B and meningococcal conjugate vaccine to children requiring immunisation as part of the national childhood vaccination
More informationSAMPLE. PGD reviewed by: Dr Tim Patterson, Chris Faldon, John Maloney, Adrian Mackenzie
Patient Group Direction for the Supply or Administration of combined Diphtheria, Tetanus, acellular Pertussis, inactivated Polio vaccine and Haemophilus type b conjugate Vaccine (Infanrix-IPV-HIB) to children
More informationCommunity Psychiatric Nurse. Consultant Psychiatrist, Substance Misuse Services
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF HEPATITIS A VACCINE (HAVRIX MONODOSE VACCINE) BY REGISTERED NURSES WORKING IN THE COMMUNITY SUBSTANCE MISUSE TEAMS Version Number : 2 Patient Group
More informationHEPATITIS A + TYPHOID VACCINE
GG&C PGD ref no: 2017/1522 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Indicated for active immunisation
More informationClinical Condition Indication:
GG&C PGD ref no: 2012/943 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation of individuals
More informationClinical Condition Indication:
Patient Group Direction ( for Health Care GG&C PGD ref no: 2018/1611 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition
More informationThis document expires on Patient Group Direction No. VI 11
Patient Group Direction (PGD) for The Administration of Combined Inactivated Hepatitis A & Hepatitis B Vaccine (Twinrix adult, Twinrix paediatric) to Adults and Children over one year by Registered Nurses
More informationCONJUGATE MENINGOCOCCAL (ACWY) VACCINE
Cumbria & Lancashire Vaccine PGD Group ADVISORY INFORMATION FOR USE WITH PATIENT SPECIFIC DIRECTION OR INDIVIDUAL PRESCRIPTION SIGNED BY GP OR NON-MEDICAL PRESCRIBER. CONJUGATE MENINGOCOCCAL (ACWY) VACCINE
More informationPatient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine
n Patient Group Direction For The Administration Of H1N1 (Swine Flu) vaccine October 2009 PGD version template-2009.1 Page 1 of 8 Rationale Patient Group Direction For The Administration Of H1N1 (Swine
More informationThis document expires on Patient Group Direction Number VI 19
Patient Group Direction (PGD) for The Administration of Pneumococcal Polysaccharide Vaccine (PPV, Pneumovax II ) to adults over 65 years and at risk groups aged 2 years and over, by Registered Nurses employed
More informationGG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1408 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationTHIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
Patient Group Direction for Pneumococcal polysaccharide vaccine VERSION: PNEUMOCOCCAL POLY-2013.1 (Pneumovax II ) Start 1 st May 2013 Expiry 30 th April 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED
More informationAdministration of Hepatitis A and B Vaccine
PRACTICE: Ref No: PGD/ONEL/2011/006 Valid from December 2011 Valid to December 2013 Supersedes PGD: Any previous PGD used to administer Twinrix Adult and Paediatric vaccine Professional groups covered
More informationCLINICAL CONTENT OF PATIENT GROUP DIRECTION FOR PNEUMOCOCCAL CONJUGATE VACCINE (Prevenar 13 )
Patient Group Direction for Pneumococcal Conjugate Vaccine (Prevenar 13 ) Version: PNEUMOCOCCAL CONJUGATE 2014.1 Start 1 st February 2014 Expiry 31 st January 2017 THIS PATIENT GROUP DIRECTION HAS BEEN
More informationChange history Version number Change details Date Updated for National ACWY programme to be implemented August June 2015.
Patient Group Direction for Conjugate Meningococcal ACWY vaccine Version: MEN ACWY CONJUGATE 2015.1 Start 1 st August 2015 Expiry 31 st July 2018 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationGG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1603 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Active immunisation
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationGG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1427 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against rotavirus.
More informationby registered nurses employed by NHS Hertfordshire or Hertfordshire GP Practices and signatories to the PGD
Notice to all staff: NHS Hertfordshire Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been
More informationDirection Number: - NECSAT 2015/001
Patient Group Direction (PGD) for the Administration of HEPATITIS A VACCINES by Registered Professionals to Individuals Accessing NHS Services in Cumbria and North East Sub Region (NHS England North) YOU
More informationDirection Number: - NECSAT 2015/004
Patient Group Direction (PGD) for the Administration of TYPHOID VACCINES (TYPHIM Vi, TYPHERIX and VIVOTIF ) by Registered Professionals to Individuals Accessing NHS Services in Cumbria and North East Sub
More informationPrescription only medicines (POMs)
Prescription only medicines (POMs) 2017 Learning objectives Explain the legal framework with which registered health care professionals can administer prescription only medicines Define the role and limitations
More informationPatient Group Direction for the Administration of Hepatitis A vaccine
Patient Group Direction for the Administration of Hepatitis A vaccine This PGD must be read in conjunction with the core PGD (Reference: NHSE(LR)/PGD/Core PGD for Immunisations), which details information
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF PROCEDURE: Medicines Procedure: Patient Group Directions for the Administration of Hepatitis B Vaccine for SABP Drug and Alcohol Teams. PURPOSE OF PROCEDURE:
More informationDirection Number: - NECSAT 2017/004
Patient Group Direction (PGD) for the Administration of TYPHOID VACCINES (TYPHIM Vi, TYPHERIX and VIVOTIF ) by Registered Professionals to Individuals Accessing NHS Services in Cumbria and North East Sub
More informationThis Patient Group Direction has been developed/reviewed in accordance with NICE guidance by:- Position of Signatory Name Signed Date
Patient Group Direction Administration of Hepatitis B Vaccine By Registered Nurses employed by GP Practices within Stafford & Surrounds Clinical Commissioning Group This Patient Group Direction has been
More informationGG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1589 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Individuals requiring active immunisation
More informationPatient Group Direction for Rotavirus vaccine Version: ROTAVIRUS (Rotarix ) Start Date: 1 st July 2013 Expiry Date:30 th June 2015
Patient Group Direction for Rotavirus vaccine Version: ROTAVIRUS-2013. 1 (Rotarix ) Start 1 st July 2013 Expiry 30 th June 2015 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st April 2016 Expiry Date: 31 st March 2019
Patient Group Direction for Varicella vaccine Version: Varicella 2016.1 Start Date: 1 st April 2016 Expiry Date: 31 st March 2019 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationPatient Group Direction No. VI 17. Kathy Wakefield/Lisa Murray. General Practices & TRFT. Relevant Clinical Lead
T i:1 Patient Group Direction (PGD) for The Administration of Meningococcal Group C Conjugate Vaccine (Meningitec /NeisVac-C /Menjugate Kit ) by Registered Nurses employed or commissioned by NHS Rotherham
More informationPATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine
PHE publications gateway number: PATIENT GROUP DIRECTION (PGD) Supply of potassium iodide 65mg tablets to adults and children exposed to, or at risk of exposure to radioactive iodine For the supply of
More informationPGD No Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 - Gardasil - September 2012
Notice to all staff: NHS Hertfordshire Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been
More informationPatient Group Direction for Varicella vaccine Version: Varicella Start Date: 1 st May 2014 Expiry Date: 30 th April 2017
Patient Group Direction for Varicella vaccine Version: Varicella 2014.1 Start Date: 1 st May 2014 Expiry Date: 30 th April 2017 THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS:
More informationDirection Number: - NECSAT 2014/017
Patient Group Direction (PGD) for the Administration of HEPATITIS B VACCINE For Infants by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees (DDT) and Cumbria,
More informationDirection Number: - NECSAT 2014/014
Patient Group Direction (PGD) for the Administration of COMBINED DIPHTHERIA, TETANUS, ACELLULAR PERTUSSIS AND INACTIVATED POLIOMYELITIS VACCINE (Repevax / Infanrix IPV ) by Registered Professionals to
More informationDirection Number: - NECSAT 2014/007
Patient Group Direction (PGD) for the Administration of COMBINED LOW DOSE DIPTHERIA, TETANUS AND INACTIVATED POLIO VACCINE (Td/IPV Revaxis ) by Registered Professionals to Individuals Accessing NHS Services
More informationNATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION
NATIONAL PATIENT GROUP DIRECTION FOR SUPPLY OF PARACETAMOL ORAL SUSPENSION 120 mg/5ml FOR PREVENTION OF POST IMMUNISATION FEVER FOLLOWING ADMINISTRATION OF MENINGOCOCCAL GROUP B VACCINE (BEXSERO ) BY AUTHORISED
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands) Patient Group Direction for the administration of Bexsero suspension for injection (Meningococcal
More informationClinical Condition Indication:
GG&C PGD ref no: 2016/1366 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Active immunisation against disease
More informationpatient group direction
REVAXIS v01 1/12 REVAXIS (DIPHTHERIA, TETANUS AND POLIOMYELITIS (INACTIVATED) VACCINE (ADSORBED, REDUCED ANTIGEN(S) CONTENT)) PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic
More informationPatient Group Directions (PGDs)
Patient Group Directions (PGDs) Document level: Trustwide (TW) Code: MP2 Issue number: 4 Lead executive Authors details Type of document Target audience Document purpose Medical Director Senior Clinical
More informationPatient Group Direction (PGD) Number :
Notice to all staff: The Patient Group Directions (PGDs) for the Central Midlands Area may only be used by members of the healthcare professions named on the title page, and only if each professional has
More informationPGD for Td/IPV. Version number: 1.1
Patient Group Direction (PGD) for the Administration of Combined Diphtheria (low dose), Tetanus, and Inactivated Poliomyelitis Vaccine (Td/IPV REVAXIS ) This PGD must be read in conjunction with the core
More informationPATIENT GROUP DIRECTION (PGD)
PHE publications gateway number: 2017015 PATIENT GROUP DIRECTION (PGD) Administration of Hepatitis B recombinant DNA (rdna) vaccine (adsorbed) to individuals who are 15 years of age or over and are on
More informationIn February 2015, the Joint Committee on Vaccination and Immunisation (JCVI) *
Background In 2015, Public Health England (PHE) reported a continued increase in meningococcal serogroup W cases in England. The rise was initially recorded in 2009 and since this time, cases have steadily
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) Salbutamol Aerosol Inhaler and salbutamol Nebulised Solution Trust Ref No 1569-34313 Local Ref (optional) Main points the document Treatment of acute
More informationAdministration of shingles (herpes zoster) vaccine (live) Zostavax. Version 7.0 updated for programme from September 2017 to August 2018
Patient Group Direction template Administration of shingles (herpes zoster) vaccine (live) Zostavax Version 7.0 updated for programme from September 2017 to August 2018 This specimen Patient Group Direction
More informationDirection Number: - NECSAT 2014/003
Patient Group Direction (PGD) for the Administration of MEASLES, MUMPS AND RUBELLA VACCINE (MMR) by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees (DDT) and
More informationExpiry Date: September 2009 Template Version: Page 1 of 7
GG&C PGD ref 2007/467 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationVersion Number: 02. Patient Group Direction drawn up by: Jayne Bruce - Deputy Director of Nursing Standards and Safety Sussex
PATIENT GROUP DIRECTION (PGD) FOR THE ADMINISTRATION OF INFLUENZA VACCINE BY REGISTERED NURSES (PEER VACCINATORS) TO STAFF WORKING FOR SUSSEX PARTNERSHIP NHS FOUNDATION TRUST Version Number: 02 Patient
More informationPatient Group Direction for the Administration of Human Papilloma Virus (HPV) Vaccine (Gardasil and Cervarix )
Patient Group Direction for the Administration of Human Papilloma Virus (HPV) Vaccine (Gardasil and Cervarix ) This PGD must be read in conjunction with the core PGD (Reference: NHSE(LR)/PGD/Core PGD for
More informationPatient Group Direction (PGD) Number (minor amendment June 2014):
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands): for use in South Midlands and Hertfordshire Patient Group Direction for the administration
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2017
Patient Group Direction For Supply Of Paracetamol Oral Suspension 120mg/5mL For Prevention Of Post Immunisation Fever Following Administration Of Meningococcal Group B Vaccine (Bexsero ) By Community Pharmacists
More informationPATIENT GROUP DIRECTION PROCEDURE
PATIENT GROUP DIRECTION PROCEDURE Date approved 2 October 2015 Version 3 Approved by Yvette Oade, Chief Medical Officer Procedure Lead Clinical Governance Lead - Medicines Management Procedure Author Karen
More informationNHS Lothian Patient Group Direction Version: 006
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION AND SUPPLY OF AZITHROMYCIN FOR TREATMENT OF CHLAMYDIA (PATIENT OR PARTNER) OR CONTACTS OF NON-SPECIFIC URETHRITIS (NSU) OR PELVIC INFLAMMATORY DISEASE (PID)
More informationDirection Number: - NECSAT 2015/016
Patient Group Direction (PGD) for the Administration of SHINGLES (Herpes Zoster) VACCINE by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees, Cumbria, Northumberland
More informationAdministration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors.
Administration of Tuberculin Purified Protein Derivative (PPD) 2TU per 0.1ml to patients attending BCG clinics with identified TB at risk factors. Special notes PPD is an unlicensed medicine and therefore
More informationCALDERDALE PRIMARY CARE TRUST
CALDERDALE PRIMARY CARE TRUST PATIENT GROUP DIRECTION FOR THE SUPPLY AND ADMINISTRATION OF MEDICINES BY NON- MEDICAL PERSONNEL Progestogen-only emergency contraception for use in Community Pharmacies APPROVED
More informationPatient Group Direction for the Administration of Haemophilus Influenzae Type b and Meningococcal C conjugated vaccine (Hib/MenC - Menitorex )
Patient Group Direction for the Administration of Haemophilus Influenzae Type b and Meningococcal C conjugated vaccine (Hib/MenC - Menitorex ) This PGD must be read in conjunction with the core PGD (Reference:
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the supply and/or administration of Paracetamol Oral Suspension 250mg/5ml (Paracetamol paediatric suspension) to children receiving treatment from NHS Borders services. This
More informationPatient Group Direction for Measles, Mumps & Rubella Vaccine. PGD Version No.: 7/2013.
Document Title: Patient Group Direction for Measles, Mumps & Rubella Vaccine Area Team Doc Ref.: PGD Version No.: 7/2013 Doc Ref.: http://www.england.nhs.uk/mids-east/ss-at/immunisations/ Author: Owner:
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationCase scenarios: Patient Group Directions
Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios
More informationProtocol for the Administration of Inactivated Influenza Vaccine to. Adults by Registered Nurses via Patient Specific Direction
This document has been reviewed in line with the Policy Alignment Process for Liverpool Community Health NHS Trust Services. It is a valid Mersey Care document, however due to organisational change this
More informationDeveloped By Name Signature Date
Patient Group Direction 2155 version 2.0 Administration / Supply of Inhaled Salbutamol in Asthma by Registered Practitioners employed by Torbay and South Devon NHS Foundation Trust Date of Introduction:
More informationPNEUMOCOCCAL VACCINE (Prevenar 13 and Pneumovax II )
Patient Group Direction (PGD) for the Administration of PNEUMOCOCCAL VACCINE (Prevenar 13 and Pneumovax II ) by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees
More informationPatient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02
More informationJacqui Seaton, Head of Medicines Management/Hitesh Patel, Pharmaceutical Adviser, NHS Telford & Wrekin CCG
Document Title: Patient Group Direction for HEPATITIS B VACCINE CCG Doc Ref.: Local Doc Ref.: Author/s: Owner: File Reference: Document Overseeing Group: PGD Version No.: 1/2016 Jacqui Seaton, Head of
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands and East (Central Midlands): for use in South Midlands and Hertfordshire Patient Group Direction for the administration
More informationDirection Number: - NECSAT 2014/012
Patient Group Direction (PGD) for the Administration of SHINGLES (Herpes Zoster) VACCINE by Registered Professionals to Individuals Accessing NHS Services in Durham, Darlington, Tees (DDT) and Cumbria,
More informationPatient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version
More informationTYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide)
TYPHERIX PRODUCT INFORMATION (Salmonella typhi Vi polysaccharide) DESCRIPTION TYPHERIX is a colourless, sterile liquid containing the cell surface Vi polysaccharide extracted from Salmonella typhi Ty2
More informationPatient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within.
NHS Grampian Patient Group Direction For The Administration Of Rotavirus Vaccine Rotarix By Nurses, Midwives and Health Visitors Working Within NHS Grampian Lead Author: Consultation Group: Approver: Medicines
More informationPATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms)
PATIENT GROUP DIRECTION SUPPLY of Emergency Hormonal Contraception To females under 25 years Levonelle 1500 (Levonorgestrel 1500 micrograms) VALID FROM: 1 st July 2016 REVIEWED DATE: 30 th June 2019 This
More informationPATIENT GROUP DIRECTION
Midlands and East (Central Midlands) PATIENT GROUP DIRECTION NHS England Midlands & East (Central Midlands) Patient Group Direction for the administration of Pneumococcal Polysaccharide Vaccine 23-valent
More informationEnhanced Service Specification. Childhood seasonal influenza vaccination programme 2017/18
Enhanced Service Specification Childhood seasonal influenza vaccination programme 2017/18 2 Enhanced Service Specification Childhood seasonal influenza vaccination programme Version number: 1 First published:
More informationPGD Version No.: 3/
Document Title: Patient Group Direction for Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - Prevenar 13 ( ) Area Team Doc Ref.: PGD Version No.: 3/2014 NHS Doc Ref.: Author: Owner:
More informationGG&C PGD ref no: 2016/1309 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2016/1309 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Prevention of shingles (herpes
More information